In to reduce the rising prevalence of diabetes and hypertension in the nation, local specialists will begin employing noninvasive technologies. In contrast to the intrusive screening techniques now in use, the health ministry on Monday acquired equipment from AstraZeneca that uses retinal scanning technology to anticipate the risk or presence of problems emerging from hypertension and diabetes. A single retinal scan will be able to detect the possibility or existence of problems, strengthening local research capabilities and enhancing the nation's NCD screening program.The computerized Non Mydriatic camera will be able to foresee hazards like eye diseases in addition to diabetes and hypertension. Health CAS Rashid Aman stated that the application and evaluation of this digital Non Mydriatic camera will advance innovation in the early diagnosis of systemic issues appearing as eye disease, effectively controlling an essential health concern. The device will be used by researchers at the Aga Khan University Hospital , Kenya Medical Research Institute, Kenyatta National Hospital, and University of Nairobi.
Traditionally, a blood pressure measuring device attached to a cuff wrapped around the upper left arm is used to test for hypertension, or more generally known as high blood pressure.
On the other hand, diabetes is tested by drawing blood, which is intrusive, more expensive, and necessitates a lengthier wait for the results. The method may not be preferred by those who loathe needles. With the new technology, a person's retina will be concurrently scanned in order to check for both diabetes and hypertension.
After that, machine learning and artificial intelligence will filter the image through a cloud-based database and compare it to millions of other retinal scans to determine whether the person has any of the conditions. It is quick, non-intrusive, and may be economical in the long run, particularly for extensive population checks.
Access to healthcare is a crucial component of AstraZeneca's sustainability strategy, and the company is always relying on science to increase the resilience and sustainability of healthcare systems, according to Ashling Mulvaney. At AstraZeneca, Mulvaney serves as vice president of global sustainability and access to healthcare.
According to the ministry, the prevalence of diabetes has increased from 2% in 2015 to 3.3% as of today, with experts predicting a further rise to 4.5% by 2025. One in four people in Kenya are known to have hypertension, yet only 8% of them are receiving treatment, and just 4% have their blood pressure under control.
Content created and supplied by: Gesora (via Opera
News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform
See More
COMMENTS